4F-MDMB-BINACA

4F-MDMB-BINACA (also known as 4F-MDMB-BUTINACA or 4F-ADB) is an indazole-based synthetic cannabinoid from the indazole-3-carboxamide family.[1] It has been used as an active ingredient in synthetic cannabis products and sold as a designer drug since late 2018.[2][3] 4F-MDMB-BINACA is an agonist of the CB1 receptor (EC50 = 7.39 nM),[4] though it is unclear whether it is selective for this target.[5] In December 2019, the UNODC announced scheduling recommendations placing 4F-MDMB-BINACA into Schedule II throughout the world.[6]

4F-MDMB-BINACA
Legal status
Legal status
  • CA: Schedule II
  • DE: Anlage II (Authorized trade only, not prescriptible)
  • UK: Class B
  • UN: Psychotropic Schedule II
Identifiers
IUPAC name
  • Methyl (S)-2-(1-(4-fluorobutyl)-1H-indazole-3-carboxamido)-3,3-dimethylbutanoate
CAS Number
PubChem CID
ChemSpider
UNII
Chemical and physical data
FormulaC19H26FN3O3
Molar mass363.433 g·mol−1
3D model (JSmol)
SMILES
  • O=C(N[C@H](C(OC)=O)C(C)(C)C)C1=NN(CCCCF)C2=C1C=CC=C2
InChI
  • InChI=1S/C19H26FN3O3/c1-19(2,3)16(18(25)26-4)21-17(24)15-13-9-5-6-10-14(13)23(22-15)12-8-7-11-20/h5-6,9-10,16H,7-8,11-12H2,1-4H3,(H,21,24)/t16-/m1/s1
  • Key:GZGKSDAMWRWYOZ-MRXNPFEDSA-N

The corresponding indole core analogue, 4F-MDMB-BICA or 4F-MDMB-BUTICA has also been widely sold as a designer drug by chemical providers on the net, first being identified in May 2020.[7]

4F-MDMB-BICA

United Kingdom

It's illegal to sell, distribute, supply, transport or trade the pharmaceutical drug under the Psychoactive Substances Act 2016.

See also

References
  1. Krotulski AJ, Mohr AL, Kacinko SL, Fogarty MF, Shuda SA, Diamond FX, et al. (September 2019). "4F-MDMB-BINACA: A New Synthetic Cannabinoid Widely Implicated in Forensic Casework". Journal of Forensic Sciences. 64 (5): 1451–1461. doi:10.1111/1556-4029.14101. PMID 31260580. S2CID 195770459.
  2. Tokarczyk, Bogdan; Jurczyk, Agnieszka; Krupińska, Justyna; Adamowicz, Piotr (June 2022). "Fatal intoxication with new synthetic cannabinoids 5F-MDMB-PICA and 4F-MDMB-BINACA—parent compounds and metabolite identification in blood, urine and cerebrospinal fluid". Forensic Science, Medicine and Pathology. doi:10.1007/s12024-022-00492-3. ISSN 1556-2891. PMID 35699867.
  3. Wagmann, Lea; Stiller, Rebecca G.; Fischmann, Svenja; Westphal, Folker; Meyer, Markus R. (July 2022). "Going deeper into the toxicokinetics of synthetic cannabinoids: in vitro contribution of human carboxylesterases". Archives of Toxicology. doi:10.1007/s00204-022-03332-z. ISSN 1432-0738. PMID 35788413.
  4. Cannaert A, Sparkes E, Pike E, Luo JL, Fang A, Kevin RC, Ellison R, Gerona R, Banister SD, Stove CP (December 2020). "Synthesis and in Vitro Cannabinoid Receptor 1 Activity of Recently Detected Synthetic Cannabinoids 4F-MDMB-BICA, 5F-MPP-PICA, MMB-4en-PICA, CUMYL-CBMICA, ADB-BINACA, APP-BINACA, 4F-MDMB-BINACA, MDMB-4en-PINACA, A-CHMINACA, 5F-AB-P7AICA, 5F-MDMB-P7AICA, and 5F-AP7AICA". ACS Chemical Neuroscience. 11 (24): 4434–4446. doi:10.1021/acschemneuro.0c00644. PMID 33253529.
  5. "4F-MDMB-BINACA(4F-MDMB-BUTINACA)" (PDF).
  6. "December 2019 – WHO: World Health Organization recommends 12 NPS for scheduling".
  7. Analytical data for 4F-MDMB-BICA. Hungarian Institute for Forensic Sciences. 28-05-2020


This article is issued from Wikipedia. The text is licensed under Creative Commons - Attribution - Sharealike. Additional terms may apply for the media files.